| Affiliation: | 1. Institute of Medical Science (IMS), Faculty of Medicine, University of Toronto , Toronto, Ontario, Canada;2. Addictions Division, Centre for Addiction and Mental Health (CAMH) , Toronto, Ontario, Canada karolina.kozak@camh.ca;4. Addictions Division, Centre for Addiction and Mental Health (CAMH) , Toronto, Ontario, Canada;5. Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto , Toronto, Ontario, Canada |
| Abstract: | ABSTRACT Introduction Rates of tobacco smoking are high in people with schizophrenia with greater difficulty of quitting smoking compared to the general population, which also relate to the increased cardiovascular and cancer risks in this co-occurring disorder. Therefore, effective smoking cessation pharmacotherapies addressing tobacco co-morbidity are imperative. |
